NPI: 1184197683 · FLORENCE, SC 29505 · General Acute Care Hospital · NPI assigned 01/07/2019
Authorized official RAE, KARYN controls 20+ related entities in our dataset. Read more
| Authorized Official | RAE, KARYN (DIRECTOR) |
| NPI Enumeration Date | 01/07/2019 |
Other providers sharing the same authorized official: RAE, KARYN
| Year | Claims | Total Paid |
|---|---|---|
| 2019 | 91,550 | $3.62M |
| 2020 | 93,086 | $4.02M |
| 2021 | 135,026 | $5.42M |
| 2022 | 181,141 | $5.90M |
| 2023 | 151,853 | $5.13M |
| 2024 | 133,791 | $4.16M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 30,417 | 25,391 | $3.26M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 13,125 | 9,184 | $1.88M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 15,014 | 13,556 | $1.79M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1,943 | 1,200 | $1.43M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 11,485 | 9,333 | $1.37M |
| A9585 | Injection, gadobutrol, 0.1 ml | 1,421 | 1,255 | $1.37M |
| 80048 | Basic metabolic panel (calcium, ionized) | 18,821 | 14,742 | $1.25M |
| 96367 | 1,791 | 1,207 | $789K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 8,342 | 7,973 | $693K |
| 36415 | Collection of venous blood by venipuncture | 43,125 | 31,246 | $690K |
| 96375 | Therapeutic injection; each additional sequential IV push | 9,806 | 7,374 | $634K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 27,182 | 24,959 | $587K |
| 80047 | 10,238 | 9,230 | $550K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4,765 | 4,588 | $483K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13,141 | 3,525 | $440K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 327 | 316 | $417K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3,028 | 1,616 | $391K |
| 86850 | 4,024 | 3,487 | $388K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5,190 | 4,235 | $383K |
| 81001 | 18,305 | 16,770 | $380K | |
| 82947 | 8,404 | 5,513 | $369K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 4,589 | 3,825 | $364K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1,772 | 1,691 | $334K |
| 81025 | 5,882 | 5,507 | $327K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3,831 | 3,639 | $305K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,954 | 2,740 | $207K |
| 84702 | 3,130 | 2,552 | $191K | |
| 71250 | 1,262 | 1,221 | $183K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 721 | 708 | $180K |
| 83735 | 15,072 | 10,765 | $175K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 46,725 | 37,867 | $166K |
| 86900 | 4,798 | 4,152 | $163K | |
| 59025 | Fetal non-stress test | 4,357 | 3,110 | $163K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 18,259 | 16,963 | $151K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,986 | 2,812 | $148K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2,038 | 1,376 | $147K |
| 82565 | 1,167 | 1,027 | $144K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3,661 | 3,557 | $136K |
| 70450 | Computed tomography, head or brain; without contrast material | 4,638 | 4,311 | $127K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2,714 | 2,037 | $124K |
| 85610 | 5,717 | 4,957 | $121K | |
| 87081 | 1,114 | 1,079 | $118K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3,300 | 2,548 | $113K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 409 | 381 | $109K |
| 71046 | Radiologic examination, chest; 2 views | 4,981 | 4,765 | $104K |
| 87070 | 718 | 628 | $100K | |
| 73630 | 1,322 | 1,240 | $99K | |
| 85027 | 11,822 | 9,710 | $95K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 952 | 939 | $90K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2,582 | 2,427 | $90K |
| 81003 | 5,568 | 5,063 | $89K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 10,317 | 9,227 | $88K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 4,918 | 4,525 | $88K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4,963 | 4,566 | $88K |
| 71045 | Radiologic examination, chest; single view | 11,457 | 10,074 | $88K |
| J2704 | Injection, propofol, 10 mg | 8,910 | 7,687 | $83K |
| 72040 | 1,040 | 1,015 | $78K | |
| 87210 | 1,093 | 1,061 | $77K | |
| 82570 | 2,624 | 2,325 | $76K | |
| 88342 | 704 | 680 | $76K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 122 | 77 | $75K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 17,052 | 14,293 | $74K |
| 77336 | 206 | 75 | $74K | |
| G0378 | Hospital observation service, per hour | 10,073 | 4,131 | $73K |
| 73030 | 1,338 | 1,257 | $72K | |
| 88304 | 830 | 815 | $72K | |
| 94010 | 302 | 294 | $72K | |
| 87807 | 1,212 | 1,172 | $72K | |
| 81002 | 627 | 567 | $71K | |
| 72100 | 1,688 | 1,631 | $71K | |
| 93971 | 542 | 511 | $67K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1,702 | 1,560 | $66K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,686 | 1,630 | $65K |
| 10060 | 96 | 91 | $64K | |
| 73610 | 838 | 796 | $63K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1,391 | 1,340 | $59K |
| 80076 | 2,696 | 2,547 | $55K | |
| 73560 | 1,174 | 1,086 | $55K | |
| 82728 | 2,094 | 1,988 | $52K | |
| 74018 | 1,346 | 1,265 | $50K | |
| 73130 | 557 | 523 | $49K | |
| 84156 | 1,741 | 1,445 | $48K | |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7,707 | 6,926 | $47K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 17,717 | 13,603 | $46K |
| 95811 | 251 | 247 | $46K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1,339 | 1,309 | $46K |
| 93017 | 1,995 | 1,901 | $44K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3,474 | 3,359 | $44K |
| 80061 | Lipid panel | 7,956 | 7,726 | $43K |
| 0002A | 809 | 803 | $43K | |
| 96376 | 3,779 | 2,423 | $42K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4,860 | 1,977 | $42K |
| 95813 | 151 | 130 | $41K | |
| 82962 | 329 | 292 | $40K | |
| 0001A | 740 | 736 | $38K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 3,669 | 1,372 | $37K |
| 82607 | 2,495 | 2,361 | $37K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 239 | 227 | $36K |
| 87077 | 2,147 | 1,851 | $35K | |
| 84439 | 3,997 | 3,808 | $32K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1,486 | 1,469 | $30K |
| 84484 | 14,904 | 9,051 | $27K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 150 | 147 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | 6,812 | 6,502 | $24K |
| 84153 | 464 | 435 | $22K | |
| 84443 | Thyroid stimulating hormone (TSH) | 9,271 | 8,641 | $20K |
| 84132 | 1,237 | 1,098 | $20K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 156 | 106 | $19K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 211 | 204 | $18K |
| 74022 | 1,009 | 951 | $18K | |
| 86140 | 2,184 | 2,027 | $17K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4,677 | 4,424 | $17K |
| 87420 | 151 | 151 | $16K | |
| 0012A | 238 | 238 | $16K | |
| 95700 | 116 | 110 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 762 | 718 | $15K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 82 | 80 | $15K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 385 | 370 | $14K |
| 86710 | 181 | 160 | $14K | |
| 73110 | 206 | 199 | $14K | |
| C9113 | Injection, pantoprazole sodium, per vial | 1,731 | 937 | $14K |
| 83880 | 4,015 | 3,497 | $13K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 242 | 224 | $13K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 4,500 | 3,269 | $13K |
| 97161 | 1,864 | 1,759 | $13K | |
| 97535 | Self-care/home management training, each 15 minutes | 1,387 | 927 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2,530 | 1,837 | $12K |
| 43235 | 425 | 415 | $11K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 812 | 788 | $11K |
| 76770 | 181 | 177 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 3,218 | 2,565 | $11K |
| 95800 | 66 | 66 | $11K | |
| 83605 | 5,224 | 4,426 | $10K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 8,665 | 6,024 | $10K |
| 97116 | 1,832 | 904 | $10K | |
| 73502 | 300 | 284 | $10K | |
| J1644 | Injection, heparin sodium, per 1000 units | 1,803 | 1,064 | $10K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 140 | 136 | $9K |
| 97597 | 213 | 137 | $9K | |
| 80197 | 1,031 | 709 | $9K | |
| 85730 | 3,487 | 3,100 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 31 | 30 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 6,944 | 6,241 | $8K |
| 93880 | 158 | 148 | $8K | |
| 94726 | 227 | 221 | $8K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 475 | 425 | $7K |
| 85379 | 2,435 | 2,289 | $7K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 82 | 78 | $7K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 1,639 | 1,554 | $7K |
| 73562 | 201 | 180 | $7K | |
| 87040 | 3,677 | 1,964 | $7K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2,331 | 2,210 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 122 | 95 | $6K |
| 82330 | 510 | 453 | $6K | |
| 82550 | 1,902 | 1,708 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 1,771 | 821 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 7,056 | 6,439 | $6K |
| 76801 | 153 | 144 | $6K | |
| J2785 | Injection, regadenoson, 0.1 mg | 1,442 | 1,380 | $6K |
| 73590 | 142 | 136 | $6K | |
| 86780 | 512 | 481 | $6K | |
| 78227 | 41 | 41 | $6K | |
| 0003A | 111 | 110 | $6K | |
| 82803 | 806 | 678 | $5K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | 14 | 14 | $5K |
| T5999 | Supply, not otherwise specified | 40 | 34 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 72 | 69 | $5K |
| 72141 | 14 | 14 | $5K | |
| 77300 | 16 | 12 | $5K | |
| 83021 | 85 | 66 | $4K | |
| C1758 | Catheter, ureteral | 278 | 269 | $4K |
| 83690 | 8,212 | 7,374 | $4K | |
| 0011A | 72 | 70 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 5,790 | 5,454 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | 1,391 | 993 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 87 | 62 | $4K |
| 84550 | 900 | 800 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 1,980 | 1,601 | $3K |
| 87205 | 388 | 321 | $3K | |
| 85014 | 927 | 705 | $3K | |
| J3480 | Injection, potassium chloride, per 2 meq | 678 | 417 | $3K |
| 82248 | 2,074 | 1,793 | $3K | |
| 83540 | 2,199 | 2,095 | $3K | |
| 86592 | 496 | 470 | $3K | |
| 76830 | Ultrasound, transvaginal | 22 | 20 | $3K |
| 72070 | 91 | 88 | $3K | |
| 82043 | 940 | 928 | $3K | |
| 76536 | 43 | 43 | $3K | |
| 73564 | 26 | 20 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 3,862 | 3,274 | $3K |
| 0071A | 51 | 51 | $3K | |
| 78226 | 13 | 13 | $3K | |
| 84145 | 924 | 810 | $3K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 1,017 | 969 | $3K |
| 0072A | 49 | 49 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | 1,246 | 979 | $3K |
| 86762 | 178 | 147 | $3K | |
| 95816 | 28 | 24 | $3K | |
| 84100 | 2,234 | 1,565 | $2K | |
| 93922 | 15 | 13 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 55 | 48 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 645 | 540 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 3,616 | 2,554 | $2K |
| 93970 | 41 | 38 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 59 | 59 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 877 | 777 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 52 | 50 | $2K |
| 99215 | Prolong outpt/office vis | 73 | 63 | $2K |
| 86803 | 79 | 78 | $2K | |
| 76642 | 60 | 56 | $2K | |
| 87340 | 215 | 181 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 18 | 12 | $2K |
| 74420 | 548 | 529 | $2K | |
| 80081 | 96 | 74 | $2K | |
| 74019 | 44 | 42 | $2K | |
| 85007 | 190 | 164 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 500 | 472 | $1K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 72 | 65 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | 33 | 12 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 36 | 36 | $1K |
| 97162 | 93 | 84 | $1K | |
| 82784 | 42 | 25 | $1K | |
| 0053A | 33 | 32 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | 575 | 389 | $1K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 12 | 12 | $1K |
| 70486 | 52 | 51 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1,334 | 1,278 | $1K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 59 | 47 | $1K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 1,016 | 966 | $959.73 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 218 | 117 | $917.08 |
| 76641 | 15 | 14 | $905.15 | |
| 83615 | 421 | 352 | $887.08 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 17 | 15 | $824.72 |
| 92526 | 21 | 12 | $814.67 | |
| 82951 | 448 | 439 | $793.63 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 75 | 72 | $753.26 |
| 82150 | 198 | 169 | $674.74 | |
| 87899 | 50 | 49 | $607.32 | |
| 82105 | 78 | 69 | $540.66 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,656 | 1,590 | $524.41 |
| 85652 | 2,328 | 2,177 | $522.25 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 492 | 473 | $470.82 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 9,189 | 7,701 | $447.33 |
| 73070 | 14 | 13 | $412.66 | |
| 95713 | 77 | 75 | $393.51 | |
| 80164 | 152 | 126 | $379.43 | |
| 82746 | 1,311 | 1,249 | $375.51 | |
| 97165 | 303 | 291 | $373.37 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 342 | 298 | $360.38 |
| 84146 | 47 | 38 | $324.81 | |
| 84155 | 12 | 12 | $308.93 | |
| 87186 | 1,539 | 1,392 | $266.39 | |
| 86038 | 55 | 55 | $230.24 | |
| 82140 | 113 | 85 | $228.31 | |
| 0124A | 19 | 14 | $225.53 | |
| 80320 | 805 | 760 | $164.88 | |
| 86706 | 13 | 12 | $163.77 | |
| 83970 | 118 | 105 | $136.73 | |
| 80329 | 147 | 140 | $130.96 | |
| 85018 | 458 | 255 | $118.58 | |
| 84295 | 648 | 590 | $116.78 | |
| 73552 | 12 | 12 | $109.24 | |
| 82374 | 13 | 12 | $104.58 | |
| 82952 | 496 | 486 | $85.03 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 16 | 16 | $64.90 |
| 84466 | 171 | 162 | $62.44 | |
| 85045 | 402 | 329 | $47.54 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 20 | 20 | $33.19 |
| 84436 | 28 | 28 | $32.03 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 484 | 459 | $26.15 |
| 82077 | 561 | 512 | $16.92 | |
| 90715 | 326 | 315 | $12.27 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 258 | 245 | $8.60 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 54 | 41 | $0.00 |
| 93458 | 458 | 435 | $0.00 | |
| 83550 | 720 | 686 | $0.00 | |
| C1769 | Guide wire | 1,343 | 1,152 | $0.00 |
| 86901 | 4,102 | 3,537 | $0.00 | |
| 96415 | 140 | 85 | $0.00 | |
| 87088 | 278 | 268 | $0.00 | |
| 96368 | 43 | 30 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 537 | 502 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 560 | 458 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 31 | 26 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 156 | 137 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 128 | 79 | $0.00 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 126 | 117 | $0.00 |
| 36430 | 21 | 15 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 477 | 439 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 203 | 181 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 42 | 27 | $0.00 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 15 | 12 | $0.00 |
| Q0247 | Injection, sotrovimab, 500 mg | 12 | 12 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 23 | 12 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 19 | 14 | $0.00 |
| J3490 | Unclassified drugs | 18 | 17 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 13 | 12 | $0.00 |
| 94644 | 34 | 33 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 30 | 12 | $0.00 |
| 94760 | 47 | 27 | $0.00 | |
| 52005 | 13 | 12 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 33 | 25 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 28 | 28 | $0.00 |
| 99152 | 1,264 | 1,189 | $0.00 | |
| 96417 | 692 | 403 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 115 | 67 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 1,147 | 991 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 260 | 179 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 46 | 41 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 353 | 345 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 421 | 273 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 14 | 14 | $0.00 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 80 | 78 | $0.00 |
| 80143 | 40 | 39 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 172 | 139 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 15 | 13 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 535 | 310 | $0.00 |
| 94729 | 225 | 221 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 88 | 73 | $0.00 |
| 80179 | 26 | 26 | $0.00 | |
| 84165 | 29 | 24 | $0.00 | |
| 86923 | 52 | 25 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 205 | 157 | $0.00 |
| 36600 | 301 | 276 | $0.00 | |
| J1245 | Injection, dipyridamole, per 10 mg | 102 | 99 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 28 | 26 | $0.00 |
| 85046 | 52 | 40 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 17 | 17 | $0.00 |
| 92610 | 13 | 13 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 26 | 25 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 12 | 12 | $0.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 15 | 13 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 15 | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 153 | 107 | $0.00 |
| 82009 | 18 | 14 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 13 | 12 | $0.00 |
| 47563 | 12 | 12 | $0.00 |